Needham Maintains Buy on Sarepta Therapeutics, Raises Price Target to $169
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum maintains a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) and raises the price target from $140 to $169.
February 16, 2024 | 6:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Gil Blum maintains a Buy rating on Sarepta Therapeutics and raises the price target from $140 to $169.
The increase in price target by a reputable analyst suggests a strong confidence in Sarepta Therapeutics' future performance. This endorsement is likely to positively influence investor sentiment and potentially increase the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100